Diagnosis of Bile Duct Cancer: New Molecular Test

1 April 2026

Diagnosis of Bile Duct Cancer: A New Molecular Test Doubles Disease Detection

A recent study conducted by researchers at the UPMC Hillman Cancer Center and the University of Pittsburgh School of Medicine has developed BiliSeq, an innovative molecular test that identifies bile duct cancer with twice the sensitivity of traditional diagnostic methods. The research, published in Gastroenterology, the flagship journal of the American Gastroenterological Association, represents a significant step forward in the early diagnosis of this rare form of cancer.

The Diagnostic Challenge of Bile Duct Cancer

When patients develop a narrowing or obstruction in the bile ducts—the channels connecting the liver, gallbladder, and intestine—clinicians face a complex diagnostic challenge: determining whether the cause is cancerous or benign. The difficulty is compounded by the anatomical location of these blockages, which makes diagnosis uncertain and can lead to significant delays in therapeutic decisions, especially in cases where the patient is indeed affected by this rare condition.

Traditionally, bile duct cancers are difficult to diagnose because they are often small, hard to reach, and surrounded by inflammation or scar tissue. Standard biopsy and cytology methods frequently fail to provide a clear diagnosis, leaving patients in a state of uncertainty that may require additional testing and, in some cases, surgery without definitive answers.

BiliSeq: An Innovative Genetics‑Based Solution

BiliSeq offers a groundbreaking solution to this diagnostic challenge. The test works by detecting genetic mutations associated with cancer in bile duct tissue, enabling identification of the disease even when tumor cells are scarce, damaged, or indistinguishable from inflammation under the microscope—a critical limitation of traditional pathology, which often fails to detect tumors and can produce false‑negative results.

The study evaluated the performance of the test in real‑world conditions over six years, involving more than 2,000 patients in the United States and analyzing nearly 3,000 bile duct tissue samples. The results were remarkable: BiliSeq detected about 82% of bile duct cancers, compared to 44% with pathology alone. Even more significant was the combined approach: when paired with traditional pathology, BiliSeq increased cancer detection to nearly 90%, with extremely rare instances of benign disease being misclassified as malignant.

A Personalized Approach to Medicine

One of the most important advantages of BiliSeq goes beyond a simple yes/no diagnostic result. The study found that the test identified treatment‑relevant genetic information in roughly one in five patients. In nearly a third of these cases, this information prompted clinicians to change the therapeutic path. This illustrates the true meaning of personalized medicine: using specific genetic data to tailor treatment to the unique characteristics of each patient.

Additionally, BiliSeq results are already being used alongside standard clinical evaluations to assist in liver transplant decision‑making for selected patients within UPMC institutions, demonstrating how this technology is already integrating into daily clinical practice.

Effectiveness in High‑Risk Patients

The study also documented BiliSeq’s performance in particularly vulnerable patient groups, including individuals with primary sclerosing cholangitis (PSC) and Hispanic patients. In these populations, pathology alone may miss up to 50% of cancers. However, when combined with BiliSeq, clinicians were able to identify up to 86% of cancer cases, offering new hope to patients with high‑risk profiles.

A Path Toward Changing Clinical Practice

This work is part of a broader effort by Pitt and UPMC to develop molecular tools that improve cancer diagnosis and therapeutic decision‑making. A previous example is PancreaSeq, a similar test developed for pancreatic cancer, now used in more than 100 institutions across the United States. As the researchers emphasized, adoption of new molecular tests requires time, but can radically transform the quality of care offered to patients.

For patients with a possible bile duct obstruction, BiliSeq means fewer tests, less waiting, and—most importantly—more treatment options. In an era in which early diagnosis and personalized medicine are increasingly crucial to clinical outcomes, this test represents a major advance in the fight against bile duct cancer, offering physicians and patients a clearer path toward recovery.

Read the press release: Pitt Study Makes New Insights into Bile Duct Cancer Detection